APA (7th ed.) Citation

SL, L., HB, L., ZY, Y., C, C., ZY, W., XS, W., . . . W, G. (2022). Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. International journal of medical sciences, 19(2), 286. https://doi.org/10.7150/ijms.68404

Chicago Style (17th ed.) Citation

SL, Liu, et al. "Gemcitabine and XCT790, an ERRα Inverse Agonist, Display a Synergistic Anticancer Effect in Pancreatic Cancer." International Journal of Medical Sciences 19, no. 2 (2022): 286. https://doi.org/10.7150/ijms.68404.

MLA (9th ed.) Citation

SL, Liu, et al. "Gemcitabine and XCT790, an ERRα Inverse Agonist, Display a Synergistic Anticancer Effect in Pancreatic Cancer." International Journal of Medical Sciences, vol. 19, no. 2, 2022, p. 286, https://doi.org/10.7150/ijms.68404.